Patrick Pirrotte

Patrick Pirrotte

Auto-generated profile, based on publicly available information

Patrick Pirrotte

Translational Genomics Research Institute

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MBMarcella Birtele
Marcella Birtele
ADAshley Del Dosso
Ashley Del Dosso
TXTiantian Xu
Tiantian Xu
TNTuan Nguyen
Tuan Nguyen
BWBrent Wilkinson
Brent Wilkinson
GQGiorgia Quadrato
Giorgia Quadrato

17 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HMHavell Markus
Havell Markus
JZJun Zhao
Jun Zhao
TCTania Contente-Cuomo
Tania Contente-Cuomo
MSMichelle D. Stephens
Michelle D. Stephens
ERElizabeth Raupach
Elizabeth Raupach
MMMuhammed Murtaza
Muhammed Murtaza
Fragmentation patterns of cell-free DNA from urine differ between healthy individuals and those with cancer.

1 September 2016 in Brain Research
Verified
Journal Article
Open access
YLYang Li
Yang Li
MCMahlon Collins
Mahlon Collins
JAJiyan An
Jiyan An
RGRachel Geiser
Rachel Geiser
TTTony Tegeler
Tony Tegeler
RBRobert Bowser
Robert Bowser
The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation results in both toxic gain and loss of normal function. Determining the protein binding partners and normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of RBPs in disease. Herein, we characterized the protein-protein interactions (PPIs) of RBM45, a RBP that localizes to inclusions in ALS/FTLD. Using immunoprecipitation coupled to mass spectrometry (IP-MS), we identified 132 proteins that specifically interact with RBM45 within HEK293 cells. Select PPIs were validated by immunoblot and immunocytochemistry, demonstrating that RBM45 associates with a number of other RBPs primarily via RNA-dependent interactions in the nucleus. Analysis of the biological processes and pathways associated with RBM45-interacting proteins indicates enrichment for nuclear RNA processing/splicing via association with hnRNP proteins and cytoplasmic RNA translation via eiF2 and eiF4 pathways. Moreover, several other ALS-linked RBPs, including TDP-43, FUS, Matrin-3, and hnRNP-A1, interact with RBM45, consistent with prior observations of these proteins within intracellular inclusions in ALS/FTLD. Taken together, our results define a PPI network for RBM45, suggest novel functions for this protein, and provide new insights into the contributions of RBM45 to neurodegeneration in ALS/FTLD. This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.

1 July 2021 in Environmental Pollution
Verified
Journal Article
Closed access
CLCorina Lesseur
Corina Lesseur
PPPatrick Pirrotte
Patrick Pirrotte
KPKhyatiben V. Pathak
Khyatiben V. Pathak
FMFabiana Manservisi
Fabiana Manservisi
DMDaniele Mandrioli
Daniele Mandrioli
JCJia Chen
Jia Chen

1 January 2022 in Environmental Research
Verified
Journal Article
Closed access
CLCorina Lesseur
Corina Lesseur
KPKhyatiben V. Pathak
Khyatiben V. Pathak
PPPatrick Pirrotte
Patrick Pirrotte
MMMelissa N. Martinez
Melissa N. Martinez
KFKelly K. Ferguson
Kelly K. Ferguson
JCJia Chen
Jia Chen

14 May 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JJJennifer X. Ji
Jennifer X. Ji
DCDawn R. Cochrane
Dawn R. Cochrane
BTBasile Tessier-Cloutier
Basile Tessier-Cloutier
SCShary Yutin Chen
Shary Yutin Chen
GHGermain Ho
Germain Ho
DHDavid Huntsman
David Huntsman
Purpose: Many rare ovarian cancer subtypes, such as small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), have poor prognosis due to their aggressive nature and resistance to standard platinum- and taxane-based chemotherapy. The development of effective therapeutics has been hindered by the rarity of such tumors. We sought to identify targetable vulnerabilities in rare ovarian cancer subtypes. Experimental Design: We compared the global proteomic landscape of six cases each of endometrioid ovarian cancer (ENOC), clear cell ovarian cancer (CCOC), and SCCOHT to the most common subtype, high-grade serous ovarian cancer (HGSC), to identify potential therapeutic targets. IHC of tissue microarrays was used as validation of arginosuccinate synthase (ASS1) deficiency. The efficacy of arginine-depriving therapeutic ADI-PEG20 was assessed in vitro using cell lines and patient-derived xenograft mouse models representing SCCOHT. Results: Global proteomic analysis identified low ASS1 expression in ENOC, CCOC, and SCCOHT compared with HGSC. Low ASS1 levels were validated through IHC in large patient cohorts. The lowest levels of ASS1 were observed in SCCOHT, where ASS1 was absent in 12 of 31 cases, and expressed in less than 5% of the tumor cells in 9 of 31 cases. ASS1-deficient ovarian cancer cells were sensitive to ADI-PEG20 treatment regardless of subtype in vitro. Furthermore, in two cell line mouse xenograft models and one patient-derived mouse xenograft model of SCCOHT, once-a-week treatment with ADI-PEG20 (30 mg/kg and 15 mg/kg) inhibited tumor growth in vivo. Conclusions: Preclinical in vitro and in vivo studies identified ADI-PEG20 as a potential therapy for patients with rare ovarian cancers, including SCCOHT.